Healthify, Novo Nordisk India Launch AI-Enabled Patient Support Program for Obesity Care
Novo Nordisk India has partnered with Healthify to launch an AI-driven, dietitian-led Patient Support Program (PSP) designed to support individuals living with obesity through structured lifestyle guidance. The initiative aims to enhance the patient experience, strengthen long-term adherence, and integrate evidence-based lifestyle management alongside obesity medications, including GLP-1 therapies, which have seen a surge in […]
GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
ABSTRACT This rapid review aimed to evaluate the effects of GLP-1 RAs on eating behaviors and eating disorder risk. Databases were searched to January 2025 to identify studies evaluating GLP-1 RA treatment for adolescents or adults with obesity or Type 2 diabetes. Eligible studies reported adverse events, changes in eating disorder risk, or eating behaviors […]
The Tim Ferriss Show Transcripts: The Random Show — The 2–2–2 Rule, The Future of AI, Bioelectric Medicine, Surviving Modern Dating, The Promises of DORAs for Alzheimer’s, and Wisdom from Anthony de Mello ( #838)
Please enjoy this transcript of another wide-ranging “Random Show” episode that I recorded with my close friend Kevin Rose (digg.com)! We explore the promises of DORAs for Alzheimer’s, Kevin’s AI stack and where AI is heading, the challenges of modern dating, wisdom from Anthony de Mello, bioelectric medicine, and much, much more. Transcripts may contain a few […]
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment – Reuters
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment Reuters
Jim Cramer on Pfizer: “I Would Hold on to It”
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think […]
When Is the Best Time to Eat Protein?
Proteins work around the clock to keep your body running. These vital molecules handle the building and repair of your tissues, from your muscles to your organs. They also play an essential role in keeping your enzymes, hormones, and immune system functioning as they should. They’re made up of smaller components called amino acids, and […]
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment
The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.
Diabetes drugs linked to slower frailty progression in older adults
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.
失败研究的细节为诺和诺德GLP-1作为阿尔茨海默病治疗方案蒙上阴影
Details of failed studies cast pall on Novo Nordisk”s GLP-1 as Alzheimer”s treatment (www.reuters.com) 09:06
The Random Show — The 2–2–2 Rule, The Future of AI, Bioelectric Medicine, Surviving Modern Dating, The Promises of DORAs for Alzheimer’s, and Wisdom from Anthony de Mello ( #838)
Welcome to another wide-ranging “Random Show” episode that I recorded with my close friend Kevin Rose (digg.com)! We explore the promises of DORAs for Alzheimer’s, Kevin’s AI stack and where AI is heading, the challenges of modern dating, wisdom from Anthony de Mello, bioelectric medicine, and much, much more. Please enjoy! This episode is brought to you […]